@exposurerisk Managing someone else’s money is the best reality check. This must include surviving a variety of market conditions including large moves that can only be explained with hindsight.
@exposurerisk watched it rise year after year. How often does an index fund sell its winners? Never! That’s why it’s so hard to beat the market-weight indexes. Track the stocks you sell and see how much your lost opportunity was. It’s humbling.
@exposurerisk What doesn’t work about TA is that it creates more trading and it turns out high turnover correlates with poorer performance. How many times have you sold a company because: lost momentum, broke a trend line, violated some trading rule etc. and then 1/2
@Mr_Derivatives 50% is a big move to predict! In that short a time frame you need a positive announcement that’s not assured. I’d go with a biotech with a drug on the verge of approval like VRTX.
@ChrisCamillo I can beat the top 1% just clicking a button:
Buy S&P Index: top 10%
Buy and hold S&P index: top 5%
Buy Nasdaq 100? Hold? Top 2%
Buy Triple Q? Long term hold? Top 1% easy.
If you don’t believe me, look at the performance history. Caveat: must survive a potential 80% drawdown.
@fitz_keith New follow. Started in the business in ‘82. Recently retired. Did it take you 3, if not 4 decades to find your market truths? Who knows what decade 5 will hold.
@CernBasher I bought SATS in January for this reason. Sold it the day before IPO after I was allocated shares of SPCX. I was disappointed that this ended up being a break even trade in spite of a successful IPO. Given the thin float of SPCX, we should be ok until lockup ends.
@liorsela Between chill and standard. When I first started using FSD, it wouldn’t slow down for speed humps. The solution was to put it in sloth mode. No more, it’s either learned by repetition or the upgrade to 14.3 changed recognition.
@CookResearcher@pepfessions You’ve got your own system for sale. Where’s the independent research that shows how effective your program is? We have plenty of science to guide us on GLP1s.